JP2020514689A5 - - Google Patents

Download PDF

Info

Publication number
JP2020514689A5
JP2020514689A5 JP2019531802A JP2019531802A JP2020514689A5 JP 2020514689 A5 JP2020514689 A5 JP 2020514689A5 JP 2019531802 A JP2019531802 A JP 2019531802A JP 2019531802 A JP2019531802 A JP 2019531802A JP 2020514689 A5 JP2020514689 A5 JP 2020514689A5
Authority
JP
Japan
Prior art keywords
antigen
biological sample
timp1
lrg1
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019531802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514689A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/066851 external-priority patent/WO2018112428A1/en
Publication of JP2020514689A publication Critical patent/JP2020514689A/ja
Publication of JP2020514689A5 publication Critical patent/JP2020514689A5/ja
Priority to JP2023011264A priority Critical patent/JP2023055806A/ja
Priority to JP2025080930A priority patent/JP2025118850A/ja
Pending legal-status Critical Current

Links

JP2019531802A 2016-12-15 2017-12-15 膵管腺癌の検出および処置のための方法 Pending JP2020514689A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023011264A JP2023055806A (ja) 2016-12-15 2023-01-27 膵管腺癌の検出および処置のための方法
JP2025080930A JP2025118850A (ja) 2016-12-15 2025-05-14 膵管腺癌の検出および処置のための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662435020P 2016-12-15 2016-12-15
US201662435024P 2016-12-15 2016-12-15
US62/435,024 2016-12-15
US62/435,020 2016-12-15
PCT/US2017/066851 WO2018112428A1 (en) 2016-12-15 2017-12-15 Methods for the detection and treatment of pancreatic ductal adenocarcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023011264A Division JP2023055806A (ja) 2016-12-15 2023-01-27 膵管腺癌の検出および処置のための方法

Publications (2)

Publication Number Publication Date
JP2020514689A JP2020514689A (ja) 2020-05-21
JP2020514689A5 true JP2020514689A5 (enExample) 2021-02-04

Family

ID=62559366

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019531802A Pending JP2020514689A (ja) 2016-12-15 2017-12-15 膵管腺癌の検出および処置のための方法
JP2023011264A Pending JP2023055806A (ja) 2016-12-15 2023-01-27 膵管腺癌の検出および処置のための方法
JP2025080930A Pending JP2025118850A (ja) 2016-12-15 2025-05-14 膵管腺癌の検出および処置のための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023011264A Pending JP2023055806A (ja) 2016-12-15 2023-01-27 膵管腺癌の検出および処置のための方法
JP2025080930A Pending JP2025118850A (ja) 2016-12-15 2025-05-14 膵管腺癌の検出および処置のための方法

Country Status (6)

Country Link
US (3) US20200182876A1 (enExample)
EP (1) EP3555628A4 (enExample)
JP (3) JP2020514689A (enExample)
KR (1) KR102549063B1 (enExample)
CN (1) CN110121647A (enExample)
WO (1) WO2018112428A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3064940B1 (en) * 2013-10-28 2019-07-03 Salivatech Co., Ltd. Salivary biomarker for pancreatic cancer
CN110646554B (zh) * 2019-09-12 2022-05-13 北京博远精准医疗科技有限公司 基于代谢组学的胰腺癌诊断标志物及其筛选方法和应用
RU2745793C1 (ru) * 2020-02-26 2021-04-01 Государственное бюджетное учреждение здравоохранения города Москвы городская клиническая больница имени С.П. Боткина департамента здравоохранения города Москвы (ГБУЗ ГКБ им. С.П. Боткина ДЗМ) Способ расчета средней продолжительности жизни у пациентов с метастатической аденокарциномой поджелудочной железы
CN115125312B (zh) * 2021-03-26 2025-07-18 中国科学院上海营养与健康研究所 用于Basal型胰腺导管腺癌(PDAC)诊断的标志物组合及其应用
CN113777309A (zh) * 2021-09-07 2021-12-10 复旦大学附属肿瘤医院 自身抗体在制备胰腺导管腺癌诊断试剂盒中的应用
CN113917008A (zh) * 2021-09-09 2022-01-11 广州济士源生物技术有限公司 质谱检测尿液中代谢物水平的产品在制备用于早期评估肠道息肉和结直肠癌产品中的应用
CN114487201A (zh) * 2022-02-09 2022-05-13 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) 鼻咽癌相关尿液标志物组合的检测试剂的应用
AU2023221839A1 (en) * 2022-02-15 2024-08-22 Kite Pharma, Inc. Predicting adverse events from immunotherapy.
WO2024059549A2 (en) * 2022-09-12 2024-03-21 Board Of Regents, The University Of Texas System Methods for the detection and treatment of pancreatic ductal adenocarcinoma

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092476A1 (en) * 2006-11-17 2010-04-15 Hanash Samir M Pancreatic cancer biomarkers
US10024857B2 (en) * 2009-10-01 2018-07-17 Med-Life Discoveries Lp Serum-based biomarkers of pancreatic cancer and uses thereof for disease detection and diagnosis
AU2012343843B2 (en) * 2011-11-30 2018-03-08 Metanomics Health Gmbh Device and methods to diagnose pancreatic cancer
US20140271621A1 (en) * 2013-03-14 2014-09-18 Abbott Laboratories Methods of prognosis and diagnosis of pancreatic cancer
EP3064940B1 (en) * 2013-10-28 2019-07-03 Salivatech Co., Ltd. Salivary biomarker for pancreatic cancer
AU2014368412A1 (en) * 2013-12-20 2016-07-07 Metanomics Health Gmbh Means and methods for diagnosing pancreatic cancer in a subject based on a metabolite panel
KR20160045547A (ko) * 2014-10-17 2016-04-27 에스케이텔레콤 주식회사 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법

Similar Documents

Publication Publication Date Title
JP2020514689A5 (enExample)
Richardson et al. Role of serological tests in the diagnosis of mold infections
Yi et al. Alpha-fetoprotein-L3 in hepatocellular carcinoma: a meta-analysis
De Vincentis et al. Breath-print analysis by e-nose for classifying and monitoring chronic liver disease: a proof-of-concept study
JP2020510816A5 (enExample)
Brekelmans et al. Smelling the diagnosis: The electronic nose as diagnostic tool in inflammatory arthritis. A case-reference study
JP2020526747A5 (enExample)
JPWO2016163539A1 (ja) 肝疾患の病態を判別する方法
Kruse et al. Development of electrochemiluminescence-based singleplex and multiplex assays for the quantification of α-synuclein and other proteins in cerebrospinal fluid
JP2008533471A5 (enExample)
Kamada et al. Reevaluation of a lectin antibody ELISA kit for measuring fucosylated haptoglobin in various conditions
WO2006026020A3 (en) Oncofetal fibronectin as a marker for disease and other conditions and methods for detection of oncofetal fibronectin
EP3440465A2 (en) Methods and systems for metabolite and/or lipid-based detection of colorectal cancer and/or adenomatous polyps
Cristaudo et al. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma
Wu et al. Development of a highly sensitive glycan microarray for quantifying AFP-L3 for early prediction of hepatitis B virus–related hepatocellular carcinoma
CN113791221A (zh) 一种检测急性主动脉夹层的生物标志物及其应用
PL1776587T3 (pl) Zastosowanie C3A i jego pochodnych jako biomarkera do leczenia gruczolaka i/lub raka jelita grubego; metody diagnostyczne i testy z ich użyciem
JP7179356B2 (ja) 代謝物分析を利用したベーチェット病の診断方法
RU2013158667A (ru) Способ диагностики болезни гоше
JP7650538B2 (ja) 血液由来エクソソームから見出した新規アルツハイマー病診断用バイオマーカー及びそれを用いたアルツハイマー病診断方法
Shi et al. CK-19 mRNA-positive cells in peripheral blood predict treatment efficacy and survival in small-cell lung cancer patients
Oberpenning et al. Semi-quantitative immunochromatographic test for prostate specific antigen in whole blood: tossing the coin to predict prostate cancer?
Hasibeder et al. Evaluation and validation of the detection of soluble triggering receptor expressed on myeloid cells 1 by enzyme-linked immunosorbent assay
Sogawa et al. Serum fibrinogen alpha C‐chain 5.9 k D a fragment as a biomarker for early detection of hepatic fibrosis related to hepatitis C virus
Kruse et al. Validation of a commercially available enzyme-linked immunoabsorbent assay for the quantification of human α-Synuclein in cerebrospinal fluid